Kyoko Matsuguma

754 total citations
16 papers, 636 citations indexed

About

Kyoko Matsuguma is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kyoko Matsuguma has authored 16 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cardiology and Cardiovascular Medicine, 5 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Kyoko Matsuguma's work include Cardiac electrophysiology and arrhythmias (3 papers), Nitric Oxide and Endothelin Effects (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Kyoko Matsuguma is often cited by papers focused on Cardiac electrophysiology and arrhythmias (3 papers), Nitric Oxide and Endothelin Effects (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Kyoko Matsuguma collaborates with scholars based in Japan, United Kingdom and United States. Kyoko Matsuguma's co-authors include Yuriko Matsumoto, Seiya Okuda, Seiji Ueda, Hidehiro Matsuoka, Tsutomu Imaizumi, Ryo Shibata, Sho‐ichi Yamagishi, Shin Irie, Shunji Matsuki and Hidetoshi Furuie and has published in prestigious journals such as Journal of the American Society of Nephrology, Alimentary Pharmacology & Therapeutics and The Journal of Clinical Pharmacology.

In The Last Decade

Kyoko Matsuguma

16 papers receiving 616 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kyoko Matsuguma Japan 12 163 159 115 113 86 16 636
Sanbao Chai China 17 135 0.8× 75 0.5× 289 2.5× 212 1.9× 36 0.4× 49 935
Yelena Blinder Japan 5 148 0.9× 249 1.6× 162 1.4× 165 1.5× 22 0.3× 6 1.2k
Jun Hokamaki Japan 19 132 0.8× 244 1.5× 241 2.1× 113 1.0× 32 0.4× 27 778
J A Lawson Australia 13 154 0.9× 96 0.6× 152 1.3× 61 0.5× 29 0.3× 18 613
Teoman Doğru Türkiye 20 160 1.0× 243 1.5× 173 1.5× 225 2.0× 66 0.8× 47 1.1k
Helena Kratochvílová Czechia 14 124 0.8× 181 1.1× 110 1.0× 131 1.2× 35 0.4× 51 552
Melih O. Babaoğlu Türkiye 13 43 0.3× 36 0.2× 108 0.9× 99 0.9× 142 1.7× 43 509
H. W. Radtke Germany 11 86 0.5× 27 0.2× 143 1.2× 75 0.7× 70 0.8× 17 579
Ander Vergara Spain 13 62 0.4× 96 0.6× 111 1.0× 115 1.0× 23 0.3× 22 519
D. Wile United Kingdom 14 79 0.5× 132 0.8× 198 1.7× 424 3.8× 53 0.6× 20 1.0k

Countries citing papers authored by Kyoko Matsuguma

Since Specialization
Citations

This map shows the geographic impact of Kyoko Matsuguma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyoko Matsuguma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyoko Matsuguma more than expected).

Fields of papers citing papers by Kyoko Matsuguma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyoko Matsuguma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyoko Matsuguma. The network helps show where Kyoko Matsuguma may publish in the future.

Co-authorship network of co-authors of Kyoko Matsuguma

This figure shows the co-authorship network connecting the top 25 collaborators of Kyoko Matsuguma. A scholar is included among the top collaborators of Kyoko Matsuguma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyoko Matsuguma. Kyoko Matsuguma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ikenaga, Takeshi, Hiroki Noguchi, Keiji Kakumoto, et al.. (2019). Effect of phytic acid on postprandial serum uric acid level in healthy volunteers: a randomized, double-blind, crossover study. Nucleosides Nucleotides & Nucleic Acids. 39(4). 504–517. 11 indexed citations
2.
Shinozawa, Tadahiro, Koki Nakamura, Masanobu Shoji, et al.. (2017). Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes. Stem Cell Reports. 8(2). 226–234. 40 indexed citations
3.
Sakamoto, Kei, Shunji Matsuki, Kyoko Matsuguma, et al.. (2017). BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides. The Journal of Clinical Pharmacology. 57(11). 1460–1471. 50 indexed citations
4.
Matsuki, Shunji, et al.. (2016). Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study. Journal of Dermatological Treatment. 27(5). 467–472. 40 indexed citations
5.
6.
Matsuguma, Kyoko, Shunji Matsuki, Kei Sakamoto, et al.. (2014). Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration: comparative study in healthy Japanese adult male subjects. Drug Development and Industrial Pharmacy. 41(3). 470–475. 2 indexed citations
7.
Stockis, Armel, Shikiko Watanabe, Elisabeth Rouits, Kyoko Matsuguma, & Shin Irie. (2014). Brivaracetam Single and Multiple Rising Oral Dose Study in Healthy Japanese Participants: Influence of CYP2C19 Genotype. Drug Metabolism and Pharmacokinetics. 29(5). 394–399. 49 indexed citations
8.
Matsuguma, Kyoko, Shunji Matsuki, Kei Sakamoto, et al.. (2014). A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men. Clinical Pharmacology in Drug Development. 4(2). 99–104. 5 indexed citations
9.
Shiramoto, Masanari, Yoshikazu Kaji, Kyoko Matsuguma, et al.. (2013). Evaluation of Assay Sensitivity and the Concentration-Effect Relationship of Moxifloxacin in a QT/QTc Study in Japan. Therapeutic Innovation & Regulatory Science. 48(2). 181–189. 1 indexed citations
10.
Ieiri, Ichiro, Kazuya Maeda, Yukio Ando, et al.. (2013). Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p‐Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs. The Journal of Clinical Pharmacology. 53(6). 654–661. 32 indexed citations
11.
Ieiri, Ichiro, Kazuya Maeda, Yukio Ando, et al.. (2012). Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. International Journal of Clinical Pharmacology and Therapeutics. 50(10). 689–700. 20 indexed citations
12.
Tsukuda, Katsunori, M Kikuchi, S. Irie, et al.. (2009). Evaluation of the 24-Hour Profiles of Physiological Insulin, Glucose, and C-Peptide in Healthy Japanese Volunteers. Diabetes Technology & Therapeutics. 11(8). 499–508. 5 indexed citations
13.
Matsumoto, Yuriko, Seiji Ueda, Sho‐ichi Yamagishi, et al.. (2007). Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease. Journal of the American Society of Nephrology. 18(5). 1525–1533. 91 indexed citations
14.
Matsuguma, Kyoko, Seiji Ueda, Sho‐ichi Yamagishi, et al.. (2006). Molecular Mechanism for Elevation of Asymmetric Dimethylarginine and Its Role for Hypertension in Chronic Kidney Disease. Journal of the American Society of Nephrology. 17(8). 2176–2183. 134 indexed citations
15.
Murakami, Makoto, et al.. (2005). Pharmacokinetics and Pharmacodynamics of Landiolol Hydrochloride, an Ultra Short-acting β1-Selective Blocker, in a Dose Escalation Regimen in Healthy Male Volunteers. Drug Metabolism and Pharmacokinetics. 20(5). 337–344. 36 indexed citations
16.
Horai, Yukio, Masahiko Kimura, Hidetoshi Furuie, et al.. (2001). Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Alimentary Pharmacology & Therapeutics. 15(6). 793–803. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sanbao Chai Breakdown of academic impact, for papers by Yelena Blinder Breakdown of academic impact, for papers by Jun Hokamaki Breakdown of academic impact, for papers by J A Lawson Breakdown of academic impact, for papers by Teoman Doğru Breakdown of academic impact, for papers by Helena Kratochvílová Breakdown of academic impact, for papers by Melih O. Babaoğlu Breakdown of academic impact, for papers by H. W. Radtke Breakdown of academic impact, for papers by Ander Vergara Breakdown of academic impact, for papers by D. Wile
Rankless by CCL
2026